Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 15 January 2021, 23:25 HKT/SGT
Share:
    

Source: Jacobson Pharma Corporation Limited
Jacobson Pharma's Proposed Spin-off and Separate Listing of JBM (Healthcare) Limited on The Main Board of The Stock Exchange of Hong Kong Limited
Declaration of Conditional Special Interim Dividend

HONG KONG, Jan 15, 2021 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced the declaration of a conditional special interim dividend by way of a distribution in specie of an aggregate of 241,777,625 JBM Shares, representing approximately 27.1% of the total number of JBM Shares in issue immediately upon completion of the proposed spin-off, to the qualifying shareholders.

As of today, the total number of issued shares of the Company ("Shares") is 1,934,221,000. Assuming there is no change in the total number of shares from today up to 29 January 2021 (the "Record Date"), the qualifying shareholders will receive one JBM Share for every eight Shares held on the Record Date.

The distribution is conditional on the public offer becoming unconditional in all respects. If such condition is not satisfied, the proposed spin-off will not take place and the distribution will not be made.

For more details, please refer to the link of announcement:
https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0115/2021011501333.pdf

About Jacobson Pharma Corporation Limited (Stock Code: 2633)
Jacobson Pharma is a leading generic drug company in Hong Kong. The Group also carries a portfolio of proprietary brands, notably Po Chai Pills, Ho Chai Kung TjiThung San, Contractubex Scar Gel, Flying Eagle Woodlok Oil, Tong Tai Chung Woodlok Oil, Doan's Ointment, Saplingtan, Shiling Oil and Col-gan Tablet, which have been widely recognised by the market. In the strategic expansion of its branded healthcare business platform, the Group has introduced health and wellness brands and products such as Dr. Freeman Flu/RSV Combo, SmartfishHealth Nutrition Products, Dr. Freeman Infection Control Product Series and Dr Freeman COVID-19 Rapid Test Kit, among other reputable brands represented in overseas markets such as Excilor and Weisen-U.

The Group aims at the continued strategic enrichment of both of its generic drug and branded healthcare portfolios through the addition of high value-added products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan, Singapore and Cambodia forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com

For media enquiries, please contact:
Strategic Financial Relations Limited
Vicky Lee Tel: (852) 2864 4834 Email: [email protected]
Rachel Ko Tel: (852) 2114 2370 Email: [email protected]
Mandy Wong Tel: (852) 2114 4900 Email: [email protected]
Fax: (852) 2527 1196




Topic: Press release summary
Sectors: Daily Finance, Daily News, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Jacobson Pharma Corporation Limited
Feb 5, 2021 16:28 HKT/SGT
JBM (Healthcare) Limited Debuts on The Main Board of SEHK
Jan 25, 2021 17:20 HKT/SGT
JBM (Healthcare) Limited to Be Spun Off from Jacobson Pharma Corporation Limited
Nov 27, 2020 20:10 HKT/SGT
Jacobson Pharma Announces FY2021 Interim Results
Sept 23, 2020 20:30 HKT/SGT
Jacobson Pharma Submits Form A1 to Spin-off Its Branded Healthcare Business
Aug 27, 2020 20:40 HKT/SGT
Jacobson Pharma Collaborates with Fosun Pharma Group to Supply Potentially 10 Million Doses of BioNTech SE's COVID-19 Vaccine Candidate in Hong Kong and Macau
June 30, 2020 22:50 HKT/SGT
Jacobson Pharma Announces FY2020 Annual Results
Feb 5, 2020 18:40 HKT/SGT
Jacobson Pharma Launches First Influenza/RSV Home Diagnostic Kit in Hong Kong and Macau
Nov 26, 2019 17:24 HKT/SGT
Jacobson Pharma Announces FY2020 Interim Results
Nov 12, 2019 21:05 HKT/SGT
Jacobson Pharma Launches Smartfish Health Nutrition Products from Norway in Greater China and Asia Pacific Region
Nov 5, 2019 23:05 HKT/SGT
Jacobson Pharma Adds Excilor to Its Portfolio to Develop China Market with Vemedia (The Netherlands)
More news >>
 News Alerts
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: